Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab ... study was supported by AstraZeneca.

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FASENRA PEN contains the active ingredient benralizumab.

(Image Credits: Pixabay) AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 J.P. Morgan Healthcare Conference, is set to transform the ...

and Fasenra (benralizumab) are positioned for indication expansion into severe asthma and chronic obstructive pulmonary disorder (COPD), respectively, during 2025. Sarin said AstraZeneca’s ...

In the study, after 28 days of treatment respiratory symptoms were found to be better with benralizumab. After 90 days, there were four times fewer people in the AstraZeneca drug group that failed ...

"This study shows that benralizumab is effective as an acute treatment of eosinophilic exacerbation." Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca ...

"This study shows that benralizumab is effective as an acute treatment of eosinophilic exacerbation." Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca, which ...